Fluctuating LDL and total cholesterol levels in older adults may indicate increased dementia and cognitive decline risk.
When helping patients understand how high levels of Lp(a ... to addressing individual risk of ASCVD is to reduce levels of low-density lipoprotein cholesterol (LDL-C), as this offers a greater ...
Five drugs are currently in development that can lower the amount of lipoprotein(a) by 65 to 98 %, three of which are in phase 3 clinical trials. Some of the new medication under development is so ...
Tracking lipid variability may be a reliable method of predicting dementia and cognitive decline among community-dwelling ...
Gen.2 Molarity assay has received 510(k) clearance from the United States Food and Drug Administration (FDA). This will be the first 510(k) cleared test of its kind available in the U.S. measuring ...